Abstract. 2-Arachidonoylglycerol (2-AG) is recognized as a potent endocannabinoid, which reduces synaptic transmission through cannabinoid CB 1 receptors, and is hydrolyzed by monoacylglycerol lipase (MGL) to arachidonic acid (AA), a cyclooxygenase substrate. We already reported that centrally administered MGL and cyclooxygenase inhibitors each reduced the intracerebroventricularly (i.c.v.) administered bombesin-induced secretion of adrenal catecholamines, while a centrally administered CB 1 -antagonist potentiated the response, indirectly suggesting bidirectional roles of brain 2-AG (stimulatory and inhibitory roles) in the bombesin-induced response. In the present study, we separately examined these bidirectional roles using 2-AG and 2-AG ether (2-AG-E) (stable 2-AG analog for MGL) in rats. 
Introduction
Bombesin, a tetradecapeptide originally isolated from the skin of the European frog Bombina bombina (1) , is a ligand for bombesin BB receptors. This peptide is not expressed in mammals, while the mammalian counterparts and the receptors are widely distributed in the mammalian brain (2) . Using bombesin, we have been examining central regulatory mechanisms of sympathoadrenomedullary outflow. Previously, we reported that intracerebroventricularly (i.c.v.) administered bombesin increased nerve activity of the adrenal branch of the splanchnic nerves, but intravenous administration of bombesin did not affect the nerve activities in rats (3). We also reported that i.c.v. administered bombesin elevated plasma levels of catecholamines (noradrenaline and adrenaline) and the elevations were both abolished by acute bilateral adrenalectomy in rats (4) . Furthermore, we reported that the peptide-induced elevations of plasma catecholamines were reduced by central pretreatment with ketoprofen (an inhibitor of cyclooxygenase) (5) and that central pretreatment with indomethacin (another inhibitor of cyclooxygenase) reduced the centrally administered arachidonic acid (a representative substrate of cyclooxygenase)-induced elevation of plasma catecholamines in rats (6) . In addition, we reported that centrally administered prostanoids, produced from arachidonic acid by cyclooxygenase-mediated mecha-
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Takahiro Shimizu 1, *, Kenjiro Tanaka 1 , and Kunihiko Yokotani nisms, elevated plasma levels of catecholamines in rats (7, 8) . These results suggest that the cyclooxygenasemediated production of active arachidonic acid metabolites (prostanoids) in the brain is involved in the bombesin-induced activation of central adrenomedullary outflow in rats. Arachidonic acid is found in cellular membrane phospholipids in position 2. Phospholipase A 2 (PLA 2 ) hydrolyzes this phospholipid sn-2 ether bond, thereby directly releasing arachidonic acid (9, 10) . However, we reported that central pretreatment with mepacrine (an inhibitor of PLA 2 ) had no effect on the centrally administered bombesin-induced elevation of plasma catecholamines (11) , indicating the involvement of a brain phospholipase other than PLA 2 in the bombesin-induced response. A phospholipase C (PLC)-mediated arachidonic acid producing pathway is also reported: 1) PLC cleaves the phosphodiester bond of membrane phospholipids, resulting in the formation of diacylglycerol (12) ; 2) diacylglycerol containing arachidonic acid in position 2 can be hydrolyzed to 2-arachidonoylglycerol (2-AG) by sn-1 selective diacylglycerol lipase (13) ; and 3) 2-AG can be further hydrolyzed by monoacylglycerol lipase to free arachidonic acid (14, 15) . Recently, using inhibitors of each lipase described above, we indirectly indicated the involvement of brain arachidonic acid generated by the brain PLC-, diacylglycerol lipase-, and monoacylglycerol lipase-mediated pathway in the bombesininduced responses in rats (11, 16) . Actually, this PLCmediated pathway has been reported to be a source of arachidonic acid from 2-AG in many cells such as bovine coronary endothelial cells (17) , rabbit aorta (18) , and murine melanoma cells (19) . These findings suggest that brain 2-AG generated by the PLC-and diacylglycerol lipase-mediated pathway functions as a source of brain arachidonic acid during the bombesin-induced elevation of plasma catecholamines in rats.
Interestingly, this arachidonic acid source 2-AG has recently been recognized as a major brain endocannabinoid for cannabinoid CB receptors (20, 21) . In the nervous system, 2-AG produced on demand from membrane phospholipids of postsynaptic neurons acts on presynaptic cannabinoid CB 1 receptors, thereby inhibiting the release of neurotransmitters (21, 22) . The 2-AG released into the synaptic cleft seems to be rapidly inactivated by uptake into neurons (23) . This 2-AGinduced retrograde signaling process seems to be involved in widespread effects, including synaptic plasticity (24) , analgesia (25) , neuroprotection and neurotoxicity (26, 27) , food intake (24, 28) , and also in the baroreflexevoked central sympathetic modulation (29) . Recently, we reported that central pretreatment with AM 251 (an antagonist of cannabinoid CB 1 receptors) or AM 404 (an uptake-inhibitor of endocannabinoid) potentiated or reduced the centrally administered bombesin-induced elevation of plasma catecholamines, respectively (16) . These results suggest that endogenously generated brain endocannabinoid (probably 2-AG) plays bidirectional roles (a stimulatory role as a precursor of prostanoids and an inhibitory role as an endocannabinoid) in the bombesin-induced elevation of plasma catecholamines in rats.
In the present study, we attempted to separately examine the bidirectional roles of 2-AG by examining the effect of centrally administered 2-AG itself on the basal plasma catecholamines levels and by examining the effect of centrally administered 2-AG ether (a stable analog of 2-AG for monoacylglycerol lipase) on the centrally administered bombesin-induced elevation of plasma catecholamines in rats.
Materials and Methods

Animals
All animal experiments were conducted in compliance with the guiding principles for the care and use of laboratory animals approved by Kochi University, which are in accordance with the "Guidelines for Proper Conduct of Animal Experiments" from the Science Council of Japan. Male Wistar rats weighing about 350 g were used (Japan SLC, Inc., Hamamatsu). Two rats were kept in one cage, and they were maintained in an air-conditioned room at 22°C -24°C under a constant day-night rhythm (14/10 h light-dark cycle, lights on at 05:00) for more than 2 weeks and given food (laboratory chow, CE-2; Clea Japan, Hamamatsu) and water ad libitum.
Experimental procedures for intracerebroventricular administration
In the morning (09:00 -10:00), the femoral vein was cannulated for infusion of saline (1.2 ml/h) and the femoral artery was cannulated for collecting blood samples, under urethane anesthesia (1.2 g/kg, i.p.). After these procedures, the rat was placed in a stereotaxic apparatus for the brain until the end of each experiment, as shown in our previous papers (30, 31) . The skull was drilled for intracerebroventricular administration of test reagents using a stainless-steel cannula (0.3 mm in outer diameter). The stereotaxic coordinates of the tip of the cannula were as follows (in mm): AP −0.8, L 1.5, V 4.0 (AP, anterior from the bregma; L, lateral from the midline; V, below the surface of the brain), according to the rat brain atlas (32) . Three hours were allowed to elapse before the application of reagents.
Drug administration
2-AG or 2-AG ether dissolved in 100% N,N-dimethylformamide (DMF) was slowly administered into the right lateral ventricle in a volume of 2.5 μl/animal using the cannula connected to a 10-μl Hamilton syringe, and the cannula was retained until the end of the experiment (Figs. 1 and 4) .
JZL184 (a selective inhibitor of monoacylglycerol lipase) dissolved in 3 μl DMF/animal or water-soluble indomethacin-Na (indomethacin) (an inhibitor of cyclooxygenase) dissolved in 5 μl sterile saline/animal was i.c.v. administered using the cannula connected to a 10-μl Hamilton syringe, which was retained in the ventricle for 15 min to avoid the leakage of these reagents and then removed from the ventricle (Figs. 2 and 3 ). 2-AG was then slowly administered as described above 30 min after the application of the reagents (Figs. 2 and 3 ).
Bombesin dissolved in 10 μl sterile saline/animal was slowly administered into the ventricle using the cannula connected to a 50-μl Hamilton syringe, and the cannula was retained until the end of the experiment (Figs. 5 -7). Rimonabant (an antagonist of cannabinoid CB 1 receptors) and/or 2-AG ether, dissolved in 3 μl DMF/animal, were i.c.v. administered 30 min before the application of bombesin, using the cannula connected to a 10-μl Hamilton syringe, which was retained for 15 min to avoid the leakage of these reagents and then removed from the ventricle (Figs. 5 and 6).
Measurement of plasma catecholamines
Blood samples (250 μl) were collected through an arterial catheter and were preserved on ice during experiments. Plasma was prepared immediately after the final sampling. Catecholamines in the plasma were extracted by the method of Anton and Sayre (33) with a slight modification and were assayed electrochemically with high performance liquid chromatography (HPLC) (30) . Briefly, after centrifugation (1500 × g for 10 min, at 4°C), the plasma (100 μl) was transferred to a centrifuge tube containing 30 mg of activated alumina, 2 ml of water deionized in a MilliQ water purification system (Millipore, Billerica, MA, USA), 1 ml of 1.5 M Tris buffer (pH 8.6) containing 0.1 M disodium EDTA, and 1 ng of 3,4-dihydroxybenzylamine as an internal standard. The tube was shaken for 10 min and the alumina was washed three times with 4 ml of ice-cold deionized water. Then, catecholamines adsorbed onto the alumina were eluted with 300 μl of 4% acetic acid containing 0.1 mM disodium EDTA. A pump (EP-300; Eicom, Kyoto), a sample injector (Model-231XL; Gilson, Villiers-le-Bel, France), and an electrochemical detector (ECD-300, Eicom) equipped with a graphite electrode were used with HPLC. Analytical conditions were as follows: detector, +450 mV potential against an Ag/AgCl reference electrode; column, Eicompack CA-50DS, 2.1 mm × 150 mm (Eicom); mobile phase, 0.1 M NaH 2 PO 4 − Na 2 HPO 4 buffer (pH 6.0) containing 50 mg/l disodium EDTA, 0.75 g/l sodium 1-octanesulfonate, and 15% methanol at a flow rate of 0.18 ml/min; injection volume, 40 μl. The amount of catecholamines in each sample was calculated using the peak height ratio relative to that of 3,4-dihydroxybenzylamine. By this assay, coefficients of variation for the intra-and inter-assay were 3.0% and 3.7%, respectively, and 0.5 pg of noradrenaline and adrenaline was accurately determined.
Immunohistochemical study on the spinally projecting neurons of the hypothalamic paraventricular nucleus (PVN)
For labeling PVN neurons innervating the spinal cord, a mono-synaptic retrograde tracer Fluoro-Gold was microinjected into the intermediolateral cell column (IML) of the thoracic spinal cord according to a previously reported method (34, 35) . Briefly, under pentobarbital anesthesia (50 mg/kg, i.p.), the rats were placed in a stereotaxic apparatus for the spinal cord until the end of the surgery. The spinal cord was exposed by dorsal laminectomy through a back midline incision with an aseptic surgical procedure. Fluoro-Gold (4% in sterile saline) was microinjected bilaterally into the IML (0.5-mm lateral from the midline and 1.0-mm below the surface of the spinal cord) at the T8 level in a volume of 200 nl on each side using a 30-G stainless-steel cannula (0.3 mm in outer diameter) at a rate of 40 nl/min. Then the muscle and skin were closed, and the rats were returned to their home-cages. The exact location of the spinal cord injection was verified by Nissl staining at the end of each experiment described below.
Fourteen days after the Fluoro-Gold injection, the rats were anesthetized with urethane (1.2 g/kg, i.p.) and the femoral vein was cannulated for infusion of saline (1.2 ml/h). Then, the rats were placed in a stereotaxic apparatus for the brain, as shown in our previous papers (34, 35) . The skull was drilled for intracerebroventricular administration of bombesin or vehicle into the right lateral ventricle using a stainless-steel cannula (0.3 mm in outer diameter) in the same manner as described above. Three hours were allowed to elapse before the start of the intracerebroventricular administration of bombesin or vehicle.
At 1 h after the administration of bombesin (1 nmol/ animal, i.c.v.) or vehicle (10 μl sterile saline/animal, i.c.v.), the rats were perfused through the left cardiac ventricle with 100 ml of 0.1 M phosphate-buffered saline (pH 7.4) followed by 350 ml of ice-cold 4% paraformaldehyde in 0.1 M phosphate buffer. Brains and spinal cords were immediately removed, post fixed in the same fixative overnight, equilibrated in 0.1 M phosphate buffer containing 20% sucrose at 4°C, coronally cut on a freezing cryostat (Cryostat HM505E; Thermo Scientific, Yokohama) at a thickness of 20 μm, and washed in 0.05 M Tris-buffered saline (pH 7.4).
Immunohistochemical analysis was performed with a slight modification of previously reported methods (34 -36) . Free-floating sections were incubated in a mixed diluent of a rabbit polyclonal antibody against diacylglycerol lipase α (1:200) and a goat polyclonal antibody against Fos (1:100) for 48 h at 4°C. After washing in 0.05 M Tris-buffered saline, the sections were incubated in a mixed diluent of Cy3-conjugated donkey anti-rabbit IgG and fluorescein isothiocyanate (FITC)-conjugated donkey anti-goat IgG antibodies (1:1000, respectively) for 2 h at room temperature in the dark and washed in 0.05 M Tris-buffered saline again. The sections were then mounted on silane-coated slides and cover slipped with VECTASHIELD ® mounting medium. All antisera were diluted in 0.05 M Tris-buffered saline containing 0.25% Triton X-100 and 0.3% bovine serum albumin. Photographs from brain sections were captured using a digital camera (DP70; Olympus, Tokyo) attached to a fluorescent microscope (AX70, Olympus) with appropriate filter sets that allow the separate visualization of Cy3 (for diacylglycerol lipase α), FITC (for Fos), and ultraviolet excitation (for Fluoro-Gold). Fluoro-Gold-labeled neurons were visualized under ultraviolet illumination. 
Treatment of data and statistics
Increments of plasma catecholamines above the basal level at each time period are expressed as pg/ml (Figs.  1 -6 ). The area under the curve (AUC) is also expressed as pg/1 h (Figs. 1 -4 ) or pg/2 h (Figs. 5 and 6 ). The number of animals in each group is shown in these figures (Figs. 1 -6 ). All values are expressed as means ± S.E.M. Statistical differences were determined using repeated-measure (treatment × time) or one-way analysis of variance (ANOVA), followed by post hoc analysis with the Bonferroni method. P values less than 0.05 were taken to indicate statistical significance.
Materials
The following materials were used: synthetic bombesin mounting medium (Vector Laboratories, Burlingame, CA, USA); Fluoro-Gold (Fluorochrome, Denver, CO, USA). All other reagents were of the highest grade available (Nacalai Tesque, Kyoto).
Results
Effect of centrally administered 2-AG on plasma catecholamines
For plasma levels of catecholamines (noradrenaline and adrenaline), repeated-measure ANOVA showed significant effects of treatment with 2-AG [noradrenaline, F(2,12) = 21.72, P < 0.05; adrenaline, F(2,12) = 13.09, P < 0.05], time [noradrenaline, F(4,47) = 12.45, P < 0.05; adrenaline, F(4,44) = 4.00, P < 0.05], and the interaction between these two factors [noradrenaline, F(8,47) = 9.00, P < 0.05; adrenaline, F(8,44) = 3.30, P < 0.05] (Fig. 1A) . One-way ANOVA also revealed significant effects of the treatments on plasma catecholamines [noradrenaline, F(2,12) = 19.77, P < 0.05; adrenaline, F(2,11) = 10.11, P < 0.05] (Fig. 1B) .
Treatment with vehicle (2.5 μl DMF/animal, i.c.v.) had no significant effect on the basal plasma levels of noradrenaline and adrenaline ( significantly elevated the plasma levels of both catecholamines (adrenaline > noradrenaline) (Fig. 1: A and B) . The responses of noradrenaline and adrenaline reached a maximum at 5 and 10 min, respectively, after the administration of 2-AG (Fig. 1A) . Intravenous administration of 2-AG (0.5 μmol/animal), however, had no effect on plasma levels of catecholamines (data not shown).
Effect of JZL184 on the centrally administered 2-AG-induced elevation of plasma catecholamines
For plasma levels of catecholamines (noradrenaline and adrenaline), repeated-measure ANOVA showed significant effects of treatments with JZL184 and 2-AG [noradrenaline, F(4,17) = 6.40, P < 0.05; adrenaline, F(4,17) = 12.55, P < 0.05], time [noradrenaline, F(4,67) = 2.99, P < 0.05; adrenaline, F(4,63) = 5.14, P < 0.05], and the interaction between these two factors [noradrenaline, F(16,67) = 2.01, P < 0.05; adrenaline, F(16,63) = 2.47, P < 0.05] (Fig. 2A) . One-way ANOVA also revealed significant effects of the treatments on plasma catecholamines [noradrenaline, F(4,16) = 7.26, P < 0.05; adrenaline, F(4,16) = 11.92, P < 0.05] (Fig. 2B) .
Treatments with vehicle-1 (3 μl DMF/animal, i.c.v.) and vehicle-2 (2.5 μl DMF/animal, i.c.v.) had no effect on the plasma levels of noradrenaline and adrenaline (Fig. 2: A and B) . Treatments with JZL184 [1.4 μmol (730 μg)/animal, i.c.v.] and vehicle-2 also had no effect on the plasma levels of both catecholamines ( (Fig. 2: A and B) .
Effect of indomethacin on the centrally administered 2-AG-induced elevation of plasma catecholamines
For plasma levels of catecholamines (noradrenaline and adrenaline), repeated-measure ANOVA showed significant effects of treatments with indomethacin and 2-AG [noradrenaline, F(4,22) = 10.62, P < 0.05; (Fig. 3A) . One-way ANOVA also revealed significant effects of the treatments on plasma catecholamines [noradrenaline, F(4,21) = 12.17, P < 0.05; adrenaline, F(4,17) = 12.56, P < 0.05] (Fig. 3B) .
Treatments with vehicle-1 (5 μl saline/animal, i.c.v.) and vehicle-2 (2.5 μl DMF/animal, i.c.v.) had no effect on the plasma levels of noradrenaline and adrenaline (Fig. 3: A and B) . Treatments with indomethacin [1.2 μmol (500 μg)/animal, i.c.v.] and vehicle-2 also had no effect on the plasma levels of both catecholamines (Fig. 3: A and B) . 
Effect of centrally administered 2-AG ether on plasma catecholamines
Repeated-measure ANOVA revealed a significant effect of the treatment with 2-AG ether on plasma adrenaline, but not on noradrenaline [noradrenaline, F(2,11) = 0.15, P = 0.86; adrenaline, F(2,11) = 5.78, P < 0.05] (Fig. 4A) . However, one-way ANOVA revealed no significant effects of the treatments on both plasma catecholamines [noradrenaline, F(2,10) = 0.24, P = 0.79; adrenaline, F(2,9) = 1.29, P = 0.32] (Fig. 4B) .
2-AG ether [0.1 and 0.5 μmol (36 and 182 μg)/animal, i.c.v.] had no significant effect on the plasma levels of noradrenaline and adrenaline at each time point with the Bonferroni method (Fig. 4A) .
Effect of 2-AG ether on the centrally administered bombesin-induced elevation of plasma catecholamines
For plasma levels of catecholamines (noradrenaline and adrenaline), repeated-measure ANOVA showed, significant effects of treatments with 2-AG ether and bombesin (Fig. 5A) . Oneway ANOVA also revealed significant effects of the treatments on plasma catecholamines [noradrenaline, F(4,19) = 16.61, P < 0.05; adrenaline, F(4,20) = 15.22, P < 0.05] (Fig. 5B) .
Treatments with vehicle-1 (3 μl DMF/animal, i.c.v.) and vehicle-2 (10 μl saline/animal, i.c.v.) had no effect on the plasma levels of noradrenaline and adrenaline (Fig. 5: A and B) . Treatments with 2-AG ether [0.1 μmol (36 μg)/animal, i.c.v.] and vehicle-2 also had no effect on the plasma levels of both catecholamines (Fig. 5: A  and B) .
Since we previously reported that bombesin (0.1, 1, and 10 nmol/animal, i.c.v.) dose-dependently elevated plasma levels of noradrenaline and adrenaline (37), we used a sub-maximum dose of 1 nmol/animal in the present study. Administration of bombesin (1 nmol/animal, i.c.v.) gradually elevated the plasma levels of noradrenaline and adrenaline (adrenaline > noradrenaline) (Fig. 5A) . The responses of noradrenaline and adrenaline reached a maximum at 60 and 30 min after the administration of this peptide, respectively. On the other hand, intravenous administration of bombesin (1 nmol/animal) had no effect on plasma levels of catecholamines (data not shown). 
Effect of rimonabant on the 2-AG ether-induced inhibition of the centrally administered bombesin-induced elevation of plasma catecholamines
For plasma levels of catecholamines (noradrenaline and adrenaline), repeated-measure ANOVA showed significant effects of treatments with (rimonabant and/or 2-AG ether) and bombesin (Fig. 6: A and B) .
Effects of bombesin on the spinally projecting PVN neurons exhibiting diacylglycerol lipase a immuno reactivity
In the rats microinjected with a retrograde tracer (Fluoro-Gold) into the spinal cord, Fluoro-Gold-labeled neurons exhibited gold fluorescent granules in the cytoplasm with a heterogeneous distribution in the PVN. These labeled neurons were abundantly observed in the dorsal cap and ventral part of the PVN (Fig. 7A) . However, Fluoro-Gold-labeled neurons were not detected in other subnuclei such as the medial and lateral parts of the PVN.
Diacylglycerol lipase α-immunoreactive cells were clearly observed in the dorsal cap (Fig. 7B ) and ventral part (Fig. 7C ) of the PVN in both vehicle (10 μl saline/ animal, i.c.v.)-and bombesin (1 nmol/animal, i.c.v.)-treated animals. In the dorsal cap and ventral part of the PVN, immunoreactivity of Fos was observed in parts of the diacylglycerol lipase α-immunoreactive cells after treatment with bombesin, but was almost absent after treatment with the vehicle (Fig. 7: B and C) . Treatment with bombesin obviously increased the number of triple-labeled neurons with Fluoro-Gold, diacylglycerol lipase α, and Fos in the dorsal cap (Fig. 7B ) and ventral part (Fig. 7C ) of the PVN. 
Discussion
2-AG generated by the PLC-and diacylglycerol lipase-mediated pathway can be hydrolyzed by monoacylglycerol lipase to free arachidonic acid. Actually, blockage of monoacylglycerol lipase activity by inhibitors or gene knockout resulted in increased 2-AG and decreased arachidonic acid levels in the mouse brain (38, 39) . Previously, we reported that central pretreatment with monoacylglycerol lipase inhibitor effectively reduced the centrally administered bombesin-induced elevation of plasma catecholamines in rats (16) . These results suggest that brain arachidonic acid produced from 2-AG (as a precursor of prostanoids) is involved in the bombesin-induced response. In the first experiment, therefore, we examined the effect of exogenous 2-AG on the basal plasma levels of catecholamines. Centrally administered 2-AG effectively elevated plasma levels of catecholamines, while peripherally administered 2-AG had no effect. Furthermore, the 2-AG-induced elevation was abolished by central pretreatment with JZL184, a potent and selective inhibitor of monoacylglycerol lipase (38) . JZL184 actually elevated brain 2-AG level in the mouse brain (38, 39) . These results suggest that the 
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Increments of plasma catecholamines above the basal level. Arrows indicate the administration of (Rimo and/or 2-AG-E)/vehicle-1 (V-1) and BB/V-2. The V-1-treated groups are the same as those in Fig. 5 . The actual values for noradrenaline and adrenaline at 0 min were 140 ± 65 and 204 ± 70 pg/ml in the 2-AG-E-pretreated group (n = 5), 327 ± 37 and 210 ± 22 pg/ml in the [2-AG-E and Rimo (30 nmol)]-pretreated group (n = 5), and 219 ± 36 and 110 ± 25 pg/ml in the [2-AG-E and Rimo (90 nmol)]-pretreated group (n = 10), respectively. B) AUC of the elevation of plasma catecholamines above the basal level for each group. *P < 0.05, # P < 0.05, when compared with the Bonferroni method to the V-1-and BB-treated group or the 2-AG-E-and BB-treated group, respectively. Other conditions are the same as those of Figs. 1 -5. brain arachidonic acid generated from 2-AG by monoacylglycerol lipase evokes the elevation of plasma catecholamines in rats.
Arachidonic acid produced from 2-AG can be further metabolized by cyclooxygenase to active metabolites, the prostanoids (39) . Previously, we reported that central pretreatment with indomethacin (an inhibitor of cyclooxygenase) reduced the centrally administered arachidonic acid-induced elevation of plasma catecholamines in rats (6) . In the next experiment, therefore, we examined whether brain cyclooxygenase is involved in the centrally administered 2-AG-induced elevation of plasma catecholamines using indomethacin. Centrally administered indomethacin effectively reduced the 2-AG-induced response, suggesting that cyclooxygenase-mediated production of brain prostanoids are involved in the 2-AG-induced elevation of plasma catecholamines in rats. Therefore, in the present experiment, centrally administered 2-AG may be hydrolyzed by monoacylglycerol lipase to free arachidonic acid, which is further metabolized to prostanoids by cyclooxygenase in the brain, thereby elevating plasma catecholamines in rats. Recently, another mechanism has been shown to generate prostanoids in addition to the mechanism described above. 2-AG can first be metabolized by cyclooxygenase and prostanoid synthases to generate glycerol esters of prostanoids (40, 41) , which are then hydrolyzed by monoacylglycerol lipase to free prostanoids. Further studies are necessary to clarify the mechanisms responsible for generating prostanoids from 2-AG in the rat brain.
In addition to a source of arachidonic acid described above, 2-AG has been also recognized as a major endogenous ligand (endocannabinoid) for cannabinoid CB receptors (20, 21) . In order to examine the role of brain 2-AG as an endocannabinoid, we used 2-AG ether (noladin ether), which functions as a ligand for cannabinoid CB receptors (42) and has been recognized as a stable 2-AG analog for monoacylglycerol lipase with an endogenous half-life of hours rather than minutes (43) . These findings suggest that 2-AG ether seems to be a cannabinoid CB receptor ligand lacking a function as a source of arachidonic acid. Actually, in the present study, centrally administered 2-AG ether at the same doses of 2-AG had no effect on the basal plasma levels of catecholamines. Therefore, we used 2-AG ether as a "pure" agonist for cannabinoid CB receptors in the next experiments. Two major cannabinoid receptors, CB 1 and CB 2 , have been identified (44, 45) . In the central nervous system, cannabinoid CB 1 receptors are mainly present, while cannabinoid CB 2 receptors are mainly distributed in peripheral and immune cells (44, 45) . 2-AG ether has been shown to be a selective cannabinoid CB 1 -receptor agonist, exhibiting K i values of 21.2 and > 3000 nM at cannabinoid CB 1 and CB 2 receptors, respectively (42) .
Recently, we reported that centrally administered bombesin-induced elevation of plasma catecholamines was potentiated by central pretreatment with a cannabinoid CB 1 -receptor antagonist and was reduced by central pretreatment with an endocannabinoid uptake-inhibitor (16) . These results suggest that brain endocannabinoid (probably 2-AG) acts on the bombesin-activated mechanisms, thereby inhibiting the bombesin-induced response through cannabinoid CB 1 receptor-mediated mechanisms in the brain, in addition to its stimulatory role as a precursor of brain prostanoids. In the present experiment, therefore, we examined the complicated inhibitory effect of 2-AG using exogenously administered 2-AG ether on the bombesin-induced response with regard to the brain cannabinoid CB 1 receptors. Centrally administered 2-AG ether effectively reduced the bombesin-induced elevation of plasma catecholamines, and this inhibition was attenuated by central treatment with rimonabant (SR141716) [a selective antagonist of cannabinoid CB 1 receptors (46)]. These results clearly suggest that endogenously generated brain 2-AG plays an inhibitory role as an endocannabinoid in the bombesin-induced elevation of plasma catecholamines in rats. 2-AG and 2-AG ether respectively exhibit K i values of 472 and 21.2 nM at cannabinoid CB 1 receptors (42, 47) , indicating that 2-AG ether has a higher affinity for the receptors than 2-AG. 2-AG acts as a full agonist at cannabinoid CB 1 receptors (21, 48), while 2-AG ether is reported as a partial agonist at the receptors expressed in Xenopus oocytes (49) and a full agonist at the receptors in human neocortex (50) . Taken together with the present results, exogenously administered 2-AG ether into the brain seems to act as a full agonist at brain cannabinoid CB 1 receptors, thereby further inhibiting the bombesin-induced elevation of plasma catecholamines in addition to the inhibition mediated by endogenous 2-AG generated by bombesin.
2-AG is produced from diacylglycerol containing arachidonic acid in position 2 by sn-1 selective diacylglycerol lipase (13) . Two isoforms of this lipase, α and β isoforms, have been identified and both are expressed in the brain (13) . In diacylglycerol lipase α-knockout mice, endocannabinoid-mediated retrograde synaptic signaling is totally absent in the cerebellum, hippocampus, striatum, and prefrontal cortex, while the signaling is intact in diacylglycerol lipase β-knockout mouse brain (51 -53) . Additionally, 2-AG content is markedly reduced in these brain regions of diacylglycerol lipase α-knockout mice, but not in diacylglycerol lipase β-knockout mice (52, 53) . These findings suggest that brain diacylglycerol lipase α is mainly responsible for the endocannabinoid 2-AG-mediated retrograde signaling. Interestingly, in the diacylglycerol lipase α-knockout mouse brain, levels of arachidonic acid decrease in parallel with those of 2-AG (51). Taken together, brain diacylglycerol lipase α seems to be involved in production of both 2-AG and arachidonic acid. In the final experiment, therefore, we examined the distribution of diacylglycerol lipase α in the hypothalamic PVN, which has been considered as a control center of the central sympatho-adrenomedullary outflow (54) .
Presympathetic neurons in the PVN send monoand poly-synaptic projections to the sympathetic preganglionic neurons residing in the IML of the spinal cord (55) . The released acetylcholine from the sympathetic pre ganglionic neurons located in T7-9 (56) activates the adrenal chromaffin cells, thereby evoking the secretion of catecholamines from the adrenal medulla. Therefore, we microinjected Fluoro-Gold, a mono-synaptic retrograde tracer, into the rat spinal cord at the T8 level for labeling presympathetic PVN neurons innervating the adrenal medulla and then examined the distribution of diacylglycerol lipase α on the Fluoro-Gold-labeled neurons using immunohistochemical procedures. FluoroGold-labeled neurons were localized in the dorsal cap and ventral part of the PVN, in accordance with previous studies showing that these regions contain neurons projecting to the spinal cord (57, 58) . In these FluoroGold-labeled spinally projecting PVN neurons, diacylglycerol lipase α was apparently expressed, and centrally administered bombesin actually activated these spinally projecting PVN neurons expressing diacylglycerol lipase α in rats. These results suggest a possibility that centrally administered bombesin activates, at least in part, the spinally projecting PVN neurons expressing diacylglycerol lipase α, thereby generating 2-AG to modulate (stimulate and inhibit) the bombesin-induced elevation of plasma catecholamines in rats. Further studies are required to identify the diacylglycerol lipase α in the pre-sympathetic, poly-synaptic neurons in the central nervous system. Previously, we reported the involvement of the brain PLC-, diacylglycerol lipase-, monoacylglycerol lipase-, and cyclooxygenase-mediated pathway in the elevation of plasma catecholamines evoked by centrally administered arginine-vasopressin and corticotropin-releasing factor (other stress-related peptides in the brain) (30, 59 -63) . These results suggest that endogenously generated brain 2-AG by the PLC-and diacylglycerol lipase-mediated pathway plays a stimulatory role as a precursor of arachidonic acid and prostanoids through the monoacylglycerol lipase-and cyclooxygenasemediated pathway in the peptide-induced responses. In addition, these peptide-induced elevations of plasma catecholamines were potentiated by central pretreatment with a cannabinoid CB 1 -receptor antagonist (61, 62) , suggesting that endogenously generated brain endocannabinoid (probably 2-AG) plays an inhibitory role in these responses. Further studies are needed to clarify the bidirectional roles of endogenous 2-AG as a precursor of prostanoids and as an endocannabinoid in these peptide-induced elevations of plasma catecholamines in rats.
Plasma catecholamines are elevated by activation of the sympatho-adrenomedullary system, which plays an important role in physiological and pathophysiological responses to stressors (64) . Because this system modulates cardiovascular and immune functions (65, 66) , excess activation of the sympatho-adrenomedullary system induced by high levels of stress may thus contribute to the development of cardiovascular diseases such as hypertension and certain diseases of the immune system (67, 68) . Therefore, in order to clarify the mechanisms of the stress-related diseases, we have been examining the central regulatory mechanisms of sympatho-adrenomedullary outflow using several stress-related neuropeptides including bombesin. From the present results indicating the bidirectional roles of endogenous 2-AG, 1) drugs that inhibit brain prostanoids production such as cyclooxygenase inhibitors and 2) drugs that activate brain cannabinoid CB 1 -receptor signaling such as agonists for the receptors can be considered to be valuable for treating diseases evoked by excess activation of central sympatho-adrenomedullary outflow. Actually, in spontaneous hypertensive rats, decreased cannabinoid CB 1 -receptor signaling in the nucleus of the solitary tract seems to attenuate baroreflex-evoked central sympathetic modulation, thereby inducing the hypertensive phenotype (69) . These results suggest that drugs activating the CB 1 -receptor signaling may be beneficial for clinical application to hypertensive disorders. Further studies are needed to clarify the roles of endogenous 2-AG for treating the central sympathoadrenomedullary outflow-induced disorders.
In summary, we demonstrated here that 2-AG in the brain plays bidirectional roles, a stimulatory role as an arachidonic acid precursor on the basal state and an inhibitory role as an endocannabinoid in the bombesininduced activation of central adrenomedullary outflow in rats.
